GSK2118436: Completed Phase III enrollment

GlaxoSmithKline disclosed in its 3Q11 earnings that it completed enrollment of the open-label, international Phase III BRF113683 trial comparing 150 mg GSK2118436 twice daily vs. 1,000 mg/m 2 IV dacar...